Madrigal Pharmaceuticals, Inc.
A maker of Rezdiffra, the first FDA-approved drug for MASH, a fatty-liver disease that can lead to serious liver damage. Founded in 2011 by Dr. Rebecca Taub to develop a thyroid-hormone molecule she had rediscovered, the company took its name from the madrigal, a Renaissance choral song, as a nod to restoring harmony to the liver. Fun quirk: it's unrelated to the fictional Madrigal Electromotive from Breaking Bad.
No changes, except that the Reporting Person no longer serves as Chief Medical Officer of the Issuer; the Reporting Person serves as Senior Scientific and Medical Advisor of the Issuer and continues to serve as a member of the Board of Directors of the Issuer.
No changes, except that the Reporting Person no longer serves as Chairman of the Board and Chief Executive Officer of the Issuer; the Reporting Person continues to serve as a member of the Board of Directors of the Issuer.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13G/APassive | 4.6% | 1.07M | Jul 29, 2026 |
| JANUS HENDERSON GROUP PLC | 13G/APassive | 8.8% | 2.02M | May 15, 2026 |
| PAULSON & CO. INC. | 13G/APassive | 6.1% | 1.39M | May 15, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Rebecca Taub, M.D. | 13D/AActivist | 7.8% | 1.81M | Dec 12, 2025 |
No changes, except that the Reporting Person no longer serves as Chief Medical Officer of the Issuer; the Reporting Person serves as Senior Scientific and Medical Advisor of the Issuer and continues to serve as a member of the Board of Directors of the Issuer. | ||||
| Paul A Friedman, M.D. | 13D/AActivist | 7.8% | 1.81M | Dec 12, 2025 |
No changes, except that the Reporting Person no longer serves as Chairman of the Board and Chief Executive Officer of the Issuer; the Reporting Person continues to serve as a member of the Board of Directors of the Issuer. | ||||